Difficult-to-Cure Populations with Chronic Hepatitis C: Vanishing in the Direct-Acting Antiviral Era?

Hepatology

Volumn 62, Issue 1, 2015, Pages 4-7

  Terrault, Norah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CHILD PUGH SCORE; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; EDITORIAL; END STAGE RENAL DISEASE; GENOTYPE; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; LIVER GRAFT; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT FAILURE; VIRAL CLEARANCE; COMPLICATION; GASTROENTEROLOGY; HEPATITIS C, CHRONIC; TRENDS;

ANTIVIRAL AGENTS; GASTROENTEROLOGY; HEPATITIS C, CHRONIC; HUMANS;

EID: 84932613679     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27892     Document Type: Editorial

References (16)

1. Naggie S, Cooper C, Saag M, Yang J, Stamm L, Pang PS, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. Conference on Retroviruses and Opportunistic Infections (CROI) 2015. February 23-26, 2015; Seattle, WALB152.
2. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al.; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312:353-361.
3. Kaur K, Gandhi MA, Slish J. Drug-drug interactions among hepatitis C virus (HCV) and human immunodeficiency virus (HIV) medications. Infect Dis Ther 2015 Apr 21. doi: 10.1007/s40121-015-0061-2. [Epub ahead of print]
4. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://hcvguidelines.org. Accessed May 14, 2015.
5. Reddy K, Everson G, Flamm S, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post- transplant recurrence: preliminary results of a prospective, multicenter study. Abstract 8. AASLD 2014, Boston, MA, November 8-11. 2014.
6. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015 Feb 26. doi: 10.1002/hep.27770. [Epub ahead of print]
7. Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown R, Jr., et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/r/ABT-267+ABT-333+ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. J Hepatol 2014;60(Suppl1):S47.
8. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015;61:1485-1494.
9. Saxena V, Nyberg L, Pauly M, Ready J, Luc Szpakowski JL, Piasecki B, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis: a matched analysis. Hepatology 2015; doi: 10.1002/hep.27922.
10. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015 Apr 4. doi: 10.1002/hep.27826. [Epub ahead of print]
11. Foster G, McLauchlan J, Irving WL, Cheung M, Hudson B, Verma S, Agarwal K; HCV Research UK EAP Group. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and Abstract O002 3. EASL 2015, April 22-26, Vienna, Austria.
12. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat 2013;20:669-677.
13. Everson G, Tram T, Towner W, Davis MN, Wyles D, Nahass R, et al. Safety and efficacy of treatment with interferon-free, ribavirin-free combination of sofosbuvir+GS-5816 for 12 weeks in treatment naive patients with genotypes 1-6 HCV infection. EASL 2014, April 9-13, London, UK. Abstract O111.
14. Espinosa M, Martin-Malo A, varez de Lara M, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001;16:1669-1674.
15. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski M, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. Presented at the 50th International Liver Congress (ILC); April 22-26; Vienna, Austria. Abstract L01.
16. Roth D, Nelson D, Bruchfeld A, Liapakis AM, Silva M, Monsour H, et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. EASL 2015, April 22-26, Vienna, Austria. Abstract: LP02.